This study investigates intraductal papillary mucinous neoplasms (IPMN) and their progression to pancreatic ductal adenocarcinoma. The purpose is to identify and validate biomarkers that can distinguish between low-risk and high-risk IPMN progression.
The study focuses on evaluating the biology and malignant potential of IPMN. This study evaluates clinical management by identifying patients who may benefit from therapeutic intervention or surgical resection.
- Who can participate: Adults aged 18 years or older with a diagnosis of indolent IPMN under monitoring, or malignant IPMN or resectable pancreatic adenocarcinoma with associated IPMN, can participate. Participants must provide written informed consent.
- Study details: Participants will undergo evaluations to identify and validate biomarkers for IPMN progression.
How understandable was the trial content above?
Hard to understand
Easy to understand